We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Outperforms Expert Pathologists in Predicting Lung Cancer Spread

By LabMedica International staff writers
Posted on 12 Mar 2024
Print article
Image: AI outperformed expert pathologists in predicting which lung cancer cases are likely to metastasize (Photo courtesy of Shutterstock/Kateryna Kon)
Image: AI outperformed expert pathologists in predicting which lung cancer cases are likely to metastasize (Photo courtesy of Shutterstock/Kateryna Kon)

For years, the medical community has been struggling with the challenge of predicting which lung cancer patients are most likely to experience metastasis. This knowledge is crucial for treating early-stage non-small cell lung cancer (NSCLC) patients, as it influences whether they should undergo aggressive treatments like chemotherapy or radiation after lung surgery. Over half of stage I–III NSCLC patients eventually face brain metastasis, but for many others, such intensive treatments are unnecessary. Now, researchers have found that artificial intelligence (AI) could be a promising tool in aiding physicians with these critical decisions.

A groundbreaking pilot study conducted by Caltech (Pasadena, CA, USA) and Washington University School of Medicine in St. Louis (WUSTL, St. Louis, Mo, USA) revealed AI's capability to outperform expert pathologists in predicting the likelihood of cancer metastasis in NSCLC patients. The study involved training a deep-learning network, a sophisticated type of AI program, using hundreds of thousands of image tiles derived from biopsy images of 118 NSCLC patients. These images are typically reviewed by pathologists for cell abnormalities indicating cancer progression. The AI was tested with 40 additional biopsy images to assess its ability to predict brain metastases, demonstrating a striking 87% accuracy, surpassing the 57% accuracy rate of four expert pathologists.

Notably, the AI's predictions were even more accurate for the earliest-stage NSCLC patients (stage I) and were based on standard microscopic slides. The researchers believe that incorporating more data, such as disease severity and biomarkers, could enhance the AI's predictive capabilities. However, the researchers caution that this is just an initial step, and a larger study is necessary to validate these findings. Interestingly, the AI doesn't explicitly reveal the factors influencing its predictions, prompting ongoing research to decode the complex tumor cell features and their environment it might be analyzing. Going forward, Caltech scientists aim to develop improved instrumentation and procedures for collecting uniform, high-quality biopsy images, which could further refine the accuracy of AI predictions in cancer treatment.

"Overtreatment of cancer patients is a big problem," said Changhuei Yang, the Thomas G. Myers Professor of Electrical Engineering, Bioengineering, and Medical Engineering at Caltech. "Our pilot study indicates that AI may be very good at telling us in particular which patients are very unlikely to develop brain cancer metastasis."

"Our study is an indication that AI methods may be able to make meaningful predictions that are specific and sensitive enough to impact patient management," added Richard Cote, head of the Department of Pathology & Immunology at WUSTL.

Related Links:
Caltech
WUSTL

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.